Jump Main Menu. Go directly to the main content

Sección de idiomas


Fin de la sección de idiomas

Access / Registration

Sección de utilidades

Fin de la sección de utilidades


Start of main content

Research centres : Fundación Pública Gallega de Medicina Genómica. Santiago de Compostela.

Ana Vega Gliemmo

A graduate in Pharmacy from the University of Compostela, she obtained her Doctorate with the maximum marks in the year 2000, with a work on genetic susceptibility to cancer. She is an associate of the Galician Public Foundation for Genomic Medicine, a reference centre for genetic analysis in Galicia since 2005, where she is head of the area of hereditary breast and ovarian cancer, other rare syndromes causing predisposition to cancer, and dermatological syndromes. Her health-care activity is the origin of the majority of the lines of research she works in, all of which focus on advancing knowledge of these diseases.

She is co-ordinator of the Cancer Genetics Group of the Health Research Institute in Santiago de Compostela (IDIS, accredited by the King Charles III Health Institute) and of personnel belonging to the CIBER for Rare Diseases (CIBERER).

She is the author of more than 60 papers in high-impact journals, working on more than 25 research projects, as the Principal Investigator in ten of them. She has been awarded several research prizes, among which the AEGH Prize for the best career by a young researcher stands out. She is currently directing several doctoral theses. Thus, for example, she recently directed a doctoral thesis on the Clinical and Genetic Study of Autosomal Recessive Icthyoses in Galicia, closely connected with the project that the work of this request for grants to the Ramón Areces Foundation will centre on.

She plays an active role in several National and International Research Consortia, among which the following stand out: ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) and the RADIOGENOMIC CONSORTIUM, in which she is the Spanish representative.

End of main content